Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development.

Abstract: Clusterin-derived peptides or homologues or derivatives thereof, pharmaceutical compositions including the same, methods of manufacturing the peptides, homologues, derivatives thereof and compositions including the same, and methods of treating conditions including administering the peptides, homologues, derivatives thereof and compositions including the same, are provided.

Abstract: In one embodiment, the present invention includes a retirement unit to receive and retire executed instructions. The retirement unit may include a first array to receive information at allocation and a second array to receive information after execution. The retirement unit may further include logic to calculate an event associated with an executed instruction if information associated with the executed instruction is stored in an on-demand portion of at least one of arrays. Other embodiments are described and claimed.

Abstract: The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist. The immune response induced, or enhanced, in the neonatal host can be, for example, a cytokine immune response and/or a humoral immune response (e.g., antigen-specific).

Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.

Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.

Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.

Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.

Abstract: An automatic tourniquet system (10) including variable pressure cuff apparatus (60) for applying a variable pressure to a limb or artery of a patient in order to occlude blood flow thereat and control apparatus (40) for determining the operative pressure of the variable pressure cuff (20) apparatus and including apparatus for estimating the minimum effective cuff pressure required for complete occlusion.

Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, particularly BPI-deficient newborns.

Abstract: An automatic tourniquet system (10) including variable pressure cuff apparatus (60) for applying a variable pressure to a limb or artery of a patient in order to occlude blood flow thereat and control apparatus (40) for determining the operative pressure of the variable pressure cuff (20) apparatus and including apparatus for estimating the minimum effective cuff pressure required for complete occlusion.